Bispecific Antibodies in the Treatment of R/R MM

Video

An explanation of the mechanism of action of bispecific antibodies and their use in relapsed/refractory multiple myeloma treatment.

Recent Videos
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Related Content